Boehringer Ingelheim has appointed Hubertus von Baumbach as chairman of the board of managing directors with effect from June 2016.
Baumbach has been a member of the board of managing directors since 2009 and is head of the corporate board division of finance. He has also worked at Roche in the US and at Boehringer Ingelheim in Canada.
His appointment follows the move of the current chair, Andreas Barner, to the shareholders’ committee.
Christian Boehringer, chair of the shareholders’ committee, said: “This decision provided a successor who would ensure continuity whilst also looking to the future. Hubertus von Baumbach knows the corporation and its various divisions and his time on the board of managing directors has prepared him well for the company’s future challenges.
“Along with colleagues on the board of managing directors, he will continue the drive for change at Boehringer Ingelheim in order to secure the company’s independence in the long term.”
Also joining the board is Michel Pairet who will be responsible for the corporate business division of research and nonclinical development from January 1 2016. He formerly led the pharmacology unit at the research facility in Biberach